Curated news and analysis on clinical trials, drug approvals, and medical research.
A new four-marker blood test detects pancreatic cancer with 91.9% accuracy across all stages and 87.5% accuracy for early-stage disease. The test combines two newly identified proteins with existing biomarkers and can differentiate cancer from non-cancerous conditions. While promising for pancreatic cancer, most cancers still cannot be reliably diagnosed with blood tests alone.
GSK's antibody-drug conjugate risvutatug rezetecan has received Orphan Drug Designation in Japan for small-cell lung cancer, marking its sixth global regulatory designation. The decision was based on phase I trial data showing durable responses in extensive-stage SCLC patients. The drug is currently in phase III development for relapsed ES-SCLC.
The global orphan drugs market is projected to grow from $223.76 billion in 2023 to $486.51 billion by 2032, with North America leading at 38% market share. Over 500 orphan drugs are approved with more than 800 candidates in clinical trials, driven by regulatory incentives and major pharmaceutical company investments in rare disease therapies.
The global generic drugs market reached $389 billion in 2024 and is projected to grow to $675 billion by 2033. In the U.S., generics account for 91% of prescriptions but only 18% of drug spending, saving over $373 billion annually. Biosimilar adoption remains below 20% despite some products reaching over 60% market share within three years.
Fujifilm Biotechnologies has opened the UK's largest single-use biopharmaceutical CDMO facility in Teesside with a £400 million investment. The 110,000 sq ft facility features 19,000 liters of bioreactor capacity and will be operational in H1 2026. The expansion includes a new Bioprocess Innovation Centre that doubles the site's lab footprint.
Sarepta Therapeutics received FDA feedback supporting supplemental applications for AMONDYS 45 and VYONDYS 53, while New Zealand approved a Phase 1 trial for Huntington's Disease candidate SRP-1005. The company faces significant share price declines despite these developments, with analysts showing wide disagreement on valuation targets ranging from $5 to $80.
U.S. overdose deaths declined 19% year-over-year to 72,108 for the 12 months ending September 2025, but the drug market is evolving with dangerous polydrug cocktails like "pink cocaine" and "rhino tranq" that are harder to detect and reverse. These synthetic blends combine fentanyl with stimulants, sedatives, and veterinary tranquilizers, creating new public health challenges as naloxone becomes less effective against complex overdoses.
Novartis will acquire Pikavation Therapeutics for up to $3 billion to gain its PI3Kα inhibitor programs, led by SNV4818 for metastatic breast cancer. The deal includes $2 billion upfront and up to $1 billion in milestones, with completion expected in first half 2026. SNV4818 is designed to selectively target mutated PI3Kα while sparing healthy cells.
CD28 and CD38 have been identified as new therapeutic targets for peripheral T-cell lymphomas, with a trispecific antibody showing in vitro efficacy. The targets are expressed in 57% and 42% of PTCL cases respectively, covering most entities. Separately, low CD38 expression on circulating tumor-reactive T cells predicts better response to immune checkpoint inhibitors in lung cancer.
Researchers have developed new immunotherapy approaches including internal immune cell reprogramming and CD40-based therapies showing promising results in early trials. Meanwhile, glioblastoma remains resistant to current immunotherapies due to blood-brain barrier constraints, though advances in antibody engineering offer new potential strategies.
Prothena reported Q4 and full year 2025 financial results with $308.4 million in cash as partners Roche and Novo Nordisk initiated Phase 3 trials for prasinezumab and coramitug, both expected to complete in 2029.
Over 20 pharmaceutical companies are developing therapies for HER2-positive gastric cancer, with multiple Phase III trials launched in March 2026 testing novel combination treatments for advanced disease.
Meta-analysis of seven phase 2 trials shows metastasis-directed therapy plus standard care significantly improves progression-free survival and other endpoints in oligometastatic prostate cancer patients, with a near-significant trend toward improved overall survival.
Creative Biolabs has expanded its preclinical research capabilities with an upgraded rodent behavioral profiling platform for CNS drug discovery and enhanced circRNA and nucleic acid analysis platforms for gene therapy development.
The FDA has issued draft guidance creating a "Plausible Mechanism Framework" to accelerate approval of individualized therapies for ultra-rare diseases where traditional clinical trials are not feasible. The guidance focuses on gene editing and RNA-based treatments targeting specific genetic abnormalities.
US forces conducted three strikes on suspected drug-trafficking vessels, killing 11 people in the Caribbean and eastern Pacific. The attacks bring the total death toll to at least 159 since September.
Colorectal cancer diagnoses in people under 50 now account for nearly half of all new cases, prompting specialized treatment programs that use precision medicine and liquid biopsy technology to customize care based on individual tumor genetics.
Ten-year survival data show salvage focal therapy using heat or cold ablation is as effective as radical prostatectomy for treating localized prostate cancer recurrence after radiotherapy, with significantly fewer complications and better quality of life.
New AI-powered platforms enable same-day cancer treatment decisions and streamline clinical trial matching. University of Utah's μPharma chip predicts drug responses in under four hours, while City of Hope's HopeLLM system matches patients to trials across its national network.
Moderna reported Q4 revenues of $678 million, down 29.8% year-over-year but beating analyst expectations. The FDA reversed course and will review the company's mRNA flu vaccine application.
